Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Rescue Plan Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations - Issues related to contact lenses (FSGG)
American Rescue Plan Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2022 · fourth_quarter · Q4
- HR 5214, "To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.", regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD") - Issues related to US Treasury implementation of new corporate alternative minimum tax - Issues related to WTO TRIPS agreement
Source: Senate LDA
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations
American Rescue Plan Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations
American Rescue Plan Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations - Issues related to contact lenses (FSGG)
Dr. Lorna Breen Health Care Provider Protection Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Dr. Lorna Breen Health Care Provider Protection Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Dr. Lorna Breen Health Care Provider Protection Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Dr. Lorna Breen Health Care Provider Protection Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Protecting Seniors Through Immunization Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Protecting Seniors Through Immunization Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Protecting Seniors Through Immunization Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Protecting Seniors Through Immunization Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
Creating a Respectful and Open World for Natural Hair Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Creating a Respectful and Open World for Natural Hair Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Creating a Respectful and Open World for Natural Hair Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", regarding the expansion of the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Creating a Respectful and Open World for Natural Hair Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, Humane Cosmetics Act - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
PFAS Action Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Consolidated Appropriations Act, 2023
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Elijah E. Cummings Lower Drug Costs Now Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Elijah E. Cummings Lower Drug Costs Now Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Elijah E. Cummings Lower Drug Costs Now Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Elijah E. Cummings Lower Drug Costs Now Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Improving Seniors’ Timely Access to Care Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Improving Seniors’ Timely Access to Care Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", regarding the expansion of the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, Humane Cosmetics Act - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
PASTEUR Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
PASTEUR Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy - Issues related to carbon tax
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, Reef Safe Act - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
DIVERSE Trials Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
DIVERSE Trials Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
DIVERSE Trials Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
DIVERSE Trials Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD") - Issues related to US Treasury implementation of new corporate alternative minimum tax
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 5214, "To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.", regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD") - Issues related to US Treasury implementation of new corporate alternative minimum tax - Issues related to WTO TRIPS agreement
Inflation Reduction Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Inflation Reduction Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Inflation Reduction Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Inflation Reduction Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
HELP Copays Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
HELP Copays Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
HELP Copays Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Humane Cosmetics Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", regarding the expansion of the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Humane Cosmetics Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Humane Cosmetics Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, Humane Cosmetics Act - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Humane Cosmetics Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
Prescription Information Modernization Act of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Food and Drug Amendments of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Food and Drug Amendments of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Food and Drug Amendments of 2022
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Expressing support for the goals and ideals of National Stroke Awareness Month.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
Expressing support for the goals and ideals of National Stroke Awareness Month.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Expressing support for the goals and ideals of National Stroke Awareness Month.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Expressing support for the goals and ideals of National Stroke Awareness Month.
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Contact Lens Prescription Verification Modernization Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, Humane Cosmetics Act - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", regarding the expansion of the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
SHOP SAFE Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
No PFAS in Cosmetics Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
PASTEUR Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
Stop Settlement Slush Funds Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy - Issues related to carbon tax
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, Reef Safe Act - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
Reef Safe Act of 2021
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
DIVERSE Trials Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
DIVERSE Trials Act
Client: JOHNSON & JOHNSON SERVICES INC · Firm: JOHNSON & JOHNSON SERVICES, INC.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", regarding the expansion of the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy - Issues related to carbon tax
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions - S 3799 - "PREVENT Pandemics Act", regarding all provisions - HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions - HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue - HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions - HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations - Issues related to contact lenses (FSGG)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2022 · third_quarter · Q3
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations - Issues related to contact lenses (FSGG)
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021" - S 3799 - "PREVENT Pandemics Preparedness Act" - HR 3932/S 2079 - "PASTEUR Act of 2021" - HR 5376 - "Inflation Reduction Act", regarding provisions on prescription drugs - Issues related to Dengue - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
- HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD") - Issues related to US Treasury implementation of new corporate alternative minimum tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2022 · second_quarter · Q2
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions - HR 8299/S 4386, FDA review of certain changes to software in medical devices or predetermined change control plans - HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies - HR 5801, "HELP Copays Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2022 · first_quarter · Q1
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions - HR 5214, regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices - HR 6207/S 3357, Humane Cosmetics Act - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - HR 6007, legislation to expand access to adult vaccines under Medicare Part B, regarding all provisions - H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding provisions on drug pricing and provisions related to revenue - HR 3990/S 2047, No PFAS in Cosmetics Act - HR 2467, PFAS Action Act of 2021 - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - Issues related to clinical research diversity - Issues related to international harmonization of medical device regulation - Issues related to FDA review of certain changes to software in medical devices or predetermined change control plans - Issues related to HR ___, "Medical Device User Fee Amendments of 2022"
- HR 4800/S 2546, Reef Safe Act - Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions - Issues related to NIH Appropriations (LHHS) - Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic - Issues related to funding for USAID Appropriations (SFOPS) - Issues pertaining to funding for programs that aim to improve maternal health - Issues pertaining to cross cutting health system strengthening - Issues related to FDA Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2021 · fourth_quarter · Q4
- Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - Issues related to clean energy
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions - S 3416, "Protecting Patients from Counterfeit Medical Devices Act", a bill to expand the enforcement authority of the FDA with respect to counterfeit devices
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - Issues related to prescription drug pricing - Issues pertaining to Medicare coverage of vaccines - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - HR 446, Expressing support for the goals and ideals of National Stroke Awareness Month - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions - Issues related to clinical research diversity - S 3394, "The Emergency Use Transparency Act", regarding all provisions - HR 5376, "Build Back Better Act", regarding all provisions
- Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD") - HR 2096/S 2472 "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2021 · third_quarter · Q3
- Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2021 · second_quarter · Q2
- Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs - HR 2467, "PFAS Action Act of 2021" - HR 2238/S 984, "Break Free From Plastic Pollution Act" - HR 1512, "CLEAN Future Act"
- HR (BILL NUMBER TBD), "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases (SACKLER) Act", regarding all provisions - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to supply chain investment incentives - Issues related to international tax framework - Administration budget and infrastructure proposal related to tax - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2021 · first_quarter · Q1
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to contact lens safety - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis
- HR (BILL NUMBER TBD), "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases (SACKLER) Act", regarding all provisions - Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to supply chain investment incentives - Issues related to international tax framework - Administration budget and infrastructure proposal related to tax - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2020 · fourth_quarter · Q4
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions - Issues related to sterilization of medical devices - Issues regarding environmental sustainability
-Issues related to FY2020 Appropriations, specifically The Global Fund, Food & Drug Administration, Commerce, Interior, National Institutes of Health and Environmental Protection Agency budgets. -Issues related to frontline health workers -Issues related to maternal mortality and morbidity -H.R. 6800, "Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act", regarding all provisions -Issues related to contact lenses
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2020 · third_quarter · Q3
-Issues related to FY2020 Appropriations, specifically The Global Fund, Food & Drug Administration, Commerce, Interior, National Institutes of Health and Environmental Protection Agency budgets. -Issues related to frontline health workers -Issues related to maternal mortality and morbidity -H.R. 6800, "Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act", regarding all provisions
- Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to CFC look through. - Issues related to the implementation of the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 -"Restoring Access to Medication Act of 2019", regarding all provisions. - H.R. 748/ S. 3458, "Coronavirus Aid, Relief, and. Economic Security Act", regarding tax provisions and future stimulus bills. - Issues related to supply chain investment incentives. - Tax issues related to Puerto Rico
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2020 · second_quarter · Q2
-Issues related to FY2020 Appropriations, specifically The Global Fund, Food & Drug Administration, Commerce, Interior, National Institutes of Health and Environmental Protection Agency budgets. -Issues related to frontline health workers -Issues related to maternal mortality and morbidity -H.R. 6800, "Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act", regarding all provisions
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2020 · first_quarter · Q1
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2019 · fourth_quarter · Q4
- Issues related to miscellaneous tax bills. - Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to replacing G1LT1 global average method with a per country minimum. - Issues related to CFC look through. - Issues related to the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 -"Restoring Access to Medication Act of 2019", regarding all provisions. - H.R. 2207/S. 693 "Protect Medical Innovation Act of 2019", regarding all provisions. - Issues related to the repeal of the medical device tax and the cadillac tax
-Issues related to FY2020 Appropriations, specifically the Special Olympics, The Global Fund, Food & Drug Administration, Commerce, Interior, National Institutes of Health and Environmental Protection Agency budgets.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2019 · third_quarter · Q3
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions - Issues related to sterilization of medical devices
-Issues related to FY2020 Appropriations, specifically the Special Olympics, The Global Fund, Food & Drug Administration, Commerce, Interior, and Environmental Protection Agency budgets.
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to drug pricing reform - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2019 · second_quarter · Q2
- Issues related to miscellaneous tax bills. - Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to replacing G1LT1 global average method with a per country minimum. - Issues related to CFC look through. - Issues related to the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 - A bill to amend the Internal Revenue Code of 1986 to repeal the amendments made by the Patient Protection and Affordable Care Act which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements, regarding all provisions.
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2019 · first_quarter · Q1
-Issues related to FY2020 Appropriations, specifically the Special Olympics, The Global Fund, Food & Drug Administration, Commerce, Interior, and Environmental Protection Agency budgets.
- Issues related to miscellaneous tax bills. - Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to replacing G1LT1 global average method with a per country minimum. - Issues related to CFC look through. - Issues related to the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 - A bill to amend the Internal Revenue Code of 1986 to repeal the amendments made by the Patient Protection and Affordable Care Act which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements, regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2018 · fourth_quarter · Q4
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety - HR 6, "SUPPORT for Patients and Communities Act", regarding all provisions. - S. 2315, "Over-the-Counter Drug Safety, Innovation, and Reform Act", regarding all provisions. - HR 5333 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", regarding all provisions. - Issues related to antimicrobial resistance - Issues related to regulations on medication product packaging - H.R. 6294, " Re-Valuing Anti-Microbial Products Act of 2018", regarding all provisions - H.R. 1318, "Preventing Maternal Deaths Act of 2018", regarding all provisions
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2018 · third_quarter · Q3
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety - HR 6, "SUPPORT for Patients and Communities Act", regarding all provisions. - S. 2315, "Over-the-Counter Drug Safety, Innovation, and Reform Act", regarding all provisions. - HR 5333 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", regarding all provisions. - Issues related to antimicrobial resistance - Issues related to regulations on medication product packaging - H.R. 6294, " Re-Valuing Anti-Microbial Products Act of 2018", regarding all provisions
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2018 · second_quarter · Q2
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2018 · first_quarter · Q1
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. - HR 5492, "MOTHER Act of 2018", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2017 · fourth_quarter · Q4
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions.
- S.84/H.R.394, "Restoring Access to Medication Act of 2017", regarding all provisions. - Issues related to tax reform. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Issues related to House Blueprint - Issues related to the President's tax plan.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2017 · third_quarter · Q3
- S.84/H.R.394, "Restoring Access & Medication Act of 2017", regarding all provisions. - Issues related to tax reform. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Issues related to House Blueprint - Issues related to the President's tax plan.
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2017 · second_quarter · Q2
- S.84/H.R.394, "Restoring Access & Medication Act of 2017", regarding all provisions. - Issues related to tax reform. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Issues related to treasury debt/equity rules.
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2017 · first_quarter · Q1
- S.84/H.R.394, "Restoring Access & Medication Act of 2017", regarding all provisions. - Issues related to tax reform. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Issues related to treasury debt/equity rules.
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2016 · fourth_quarter · Q4
- S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - Issues related to FDA Funding. - Issues related to VA procurement. - S. 3067/ HR 5485 - Financial Services and General Appropriations Act of 2017 - Issues related to FTC funding.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2016 · third_quarter · Q3
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to CFC Look through permanency. - Issues related to R&D credit. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Repatriation holiday. - Issues related to Puerto Rico tax treatment. - Issues related to flexible spending accounts tax treatment. - HR 4900/ HR 5278/ S 2328, "PROMESA", regarding provisions related to Puerto Rico debt restructuring. - H.Res 770, "Providing for consideration of the bill (H.R. 5278) to establish an Oversight Board to assist the Government of Puerto Rico, including instrumentalities, in managing its public finances, and for other purposes.", regarding all provisions. - Issues related to treasury debt/equity rules.
- Issues relating to animal testing. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2016 · second_quarter · Q2
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2016 · first_quarter · Q1
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding.
- Issues relating to animal testing. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2015 · fourth_quarter · 4A
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding.
- Issues relating to animal testing. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- S 620, "Preserving Employee Wellness Programs Act", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2015 · fourth_quarter · Q4
- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - S. 1622, "The FDA Devise Accountablility Act", regarding all provisions. - S. 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2015 · third_quarter · Q3
- S 620, "Preserving Employee Wellness Programs Act", regarding all provisions.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - S. 1622, "The FDA Devise Accountablility Act", regarding all provisions. - S. 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2015 · second_quarter · Q2
- Issues relating to animal testing.
- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to Look through permanency. - Issues related to R&D credit permanency. - Issues related to Mobile Workforce. - Issues related to Cadillac Tax. - Issues related to OECD tax reports. - Issues related to Repatriation holiday.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2015 · first_quarter · Q1
- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
- Issues relating to animal testing.
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to Look through permanency. - Issues related to R&D credit permanency. - Issues related to Mobile Workforce. - Issues related to Cadillac Tax. - Issues related to OECD tax reports. - Issues related to Repatriation holiday.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2014 · fourth_quarter · Q4
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644/ HR 3969, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means and Senate Finance tax reform discussion drafts.- HR 1129 / S 1645, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions. - HR 2992, "Business Activity Tax Simplification Act", regarding all provisions. - HR 2835, "Restoring Access to Medication Act", regarding all provisions. - Issues related to OECD tax project.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2014 · third_quarter · Q3
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644/ HR 3969, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - Issues related to health care associated infections. - S 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions. - Issues related to FDA regulation of custom medical devices. - Issues related to Tricare coverage of Total Disc Arthroplasty. - Issues related to VA requirements for vendor access and credentialing. - Issues related to 21st Century Cures. - Issues related to Medicare beneficiary access. - Issues related to mobile medical applications and digital healthcare. - Issues related to FDA draft guidances on blood glucose meters. - HR 4895/ S 2902, "The Microbead Free Waters Act of 2014", regarding all provisions. - Issues related to the expanded use of unapproved drugs. - Issues related to combination products. - Issues related to the PROTECT Act (bill number pending), specifically medical mobile applications. - Issues related to Government Health Care Exclusion/ Debarment (bill number pending)
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2014 · second_quarter · Q2
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means and Senate Finance tax reform discussion drafts.- HR 1129 / S 1645, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions. - HR 2992, "Business Activity Tax Simplification Act", regarding all provisions. - HR 2835, "Restoring Access to Medication Act", regarding all provisions.
- S.1009, "Chemical Safety Improvement Act", regarding all provisions. - Ortho Clinical Diagnostics liability issue related to the EPA.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2014 · first_quarter · Q1
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - HR 2375, "Competitive Bidding for DME Delay", regarding all provisions. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - HR 2085, "Diagnostic Payment Reform", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - HR 4015, "SGR Repeal and Medicare Provider Payment Modernization Act of 2014", regarding all provisions. - Issues related to health care associated infections. - S 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions. - Issues related to FDA regulation of custom medical devices. - Issues related to Tricare coverage of Total Disc Arthroplasty. - Issues related to VA requirements for vendor access and credentialing.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2013 · fourth_quarter · Q4
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - HR 2375, "Competitive Bidding for DME Delay", regarding all provisions. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - HR 2085, "Diagnostic Payment Reform", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - S. 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013", regarding all provisions. - Issues related to health care associated infections. - S. 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2013 · third_quarter · Q3
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to appropriations/debt ceiling.
- S.1009, "Chemical Safety Improvement Act", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2013 · first_quarter · 1A
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Alzheimer's research. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - S 622, "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013", regarding all provisions. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - PL 11229, "Leahy-Smith America Invents Act" and issues related to patent trolls. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2013 · second_quarter · Q2
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to deficit reductions/fiscal cliff.
- S.1009, "Chemical Safety Improvement Act", regarding all provisions.
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2013 · first_quarter · Q1
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to deficit reductions/fiscal cliff.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means tax reform discussion draft.- HR 523, "Protect Medical Innovation Act of 2013", regarding all provisions. - HR 1295, "Medical Device Tax Elimination Act", regarding all provisions. - S 232, "Medical Device Access and Innovation Protection Act", regarding all provisions. - HR 1129, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2012 · fourth_quarter · Q4
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2012 · third_quarter · Q3
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Products. - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions. - HR 4395, "Cosmetic Safety Amendments Act of 2012", regarding all provisions. - HR 4262, "Cosmetic Safety Enhancement Act of 2012", regarding all provisions. - S 3376, "Prevent Abuse of Cough Treatment Act of 2012", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to deficit reductions/ fiscal cliff
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2012 · second_quarter · Q2
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Products. - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions. - HR 4395, "Cosmetic Safety Amendments Act of 2012", regarding all provisions. - HR 4262, "Cosmetic Safety Amendments Act of 2012", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues generating antibiotic incentives. - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Prescription Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3209, "Premarket Predictability Act of 2011", regarding all provisions. - HR 3203/ S 1943, "Novel Device Regulatory Relief Act of 2011", regarding all provisions. - HR 3230, "Keeping America Competitive Through Harmonization Act of 2011", regarding all provisions. - HR 3211, "Humanitarian Device Reform Act of 2011", regarding all provisions. - HR 3208, "Patients Come First Act of 2011", regarding all provisions. - HR 3206, "Cultivating Scientific Expertise to Foster Inovation for Patients Act of 2011", regarding all provisions. - HR 3214/ S 1972, "Food and Drug Administration Mission Reform Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - HR 3204, "Guidance Accountability and Transparency Act of 2011", regarding all provisions. - HR 3205, "FDA Renewing Efficiency From Outside Reviewer Management Act of 2011", regarding all provisons. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA. - Medical Device User Fee Act Reauthorization. - HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions. - HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions. - HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions. - S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions. - S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions. - HR 5, "Protecting Acess to Healthcare (PATH) Act", regarding all provisions. - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2012 · first_quarter · Q1
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2011 · fourth_quarter · Q4
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2011 · third_quarter · Q3
- Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions. - HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions. - Medicare Part D Letter - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions. - Issues related to Physician-owned Companies. - S 1468/ HR 2787, "Medicare Diabetes Self-Management Training Act of 2011", regarding all provisions.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues generating antibiotic incentives. - Issues regarding personalized medicine - Issues related to the Medical Device User Fee Program. - Issues related to the Better Act - Issues related to the Personalized Medicine Bill - Issues related to Diagnostics. - S. 1001, "Safe Doses Act", regarding all provisions. - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Physician Drug User Fee Act, regarding all provisions - MODERN Cures Act, regarding all provisions. - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2011 · second_quarter · Q2
- Issues related to ensuring quality of supply chain for FDA regulated products - Issues generating antibiotic incentives - Issues regarding personalized medicine - Issues related to the Prescription Drug Use Fee Program - Issues related to the Medical Device User Fee Program. - Issues related to the Prescription Drugs User Fee Act - Issues related to the Better Act - Issues related to the Personalized Medicine Bill - S. 1001, "Safe Doses Act", regarding all provisions. - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the Regulation & Reimbursement of Diagnostics", regarding all provisions.
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2011 · first_quarter · Q1
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2010 · fourth_quarter · Q4
- CMS 4138-IFC4, "Medicare Advantage and Prescription Drug Programs MIPPA Drug Formulary and Protected Classes Policies", regarding all provisions. - H.R. 684 / S. 330, "To amend title XVIII of the Social Security Act to deliver a meaningful benefit and lower prescription drug prices under the Medicare Program", regarding all provisions. - S. 883, "A bill to amend title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV", regarding all provisions. - H. R. 1616, "To amend title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV", regarding all provisions. - H. R. 1392 / S. 1221, "A bill to amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sale price", regarding all provisions. - H.R. 3138/ S. 301, "A bill to amend title XI of the Social Security Act to provide for transparancy in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP. - Implementation of Health Care Reform Bill: Medicare Wellness Benefit. - H.R. 6130, "Strengthening Medicare Anti-Fraud Measures Act of 2010", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2010 · third_quarter · Q3
- H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 3962, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - S. 3397, "An Act to Amend the Controlled Substances Act to provide for take-back Disposal of Controlled Substances in certain instances and for other purposes", regarding all provisions.
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications. - H.R. 2923, "A bill to Enhance the ability to combat Methamphetimine", regarding all provisions. - H.R. 5786, "Safe Cosmetics Act of 2010", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2010 · second_quarter · Q2
-Corporate tax deferral - H.R. 1897 / S. 803, "To amend the Internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs and for other purposes", regarding all provisions. - S. 3018, "The Bipartisan Tax Fairness and Simplification Act of 2010", regarding all provisions. - H.R. 4213, The American Jobs And Closing Tax Loopholes Act Of 2010, regarding provisions related to individual and business tax incentives.
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - H.R. 3962, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2010 · first_quarter · Q1
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1427, "To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes", regarding all provisions. - H.R. 1548 / S. 726, "To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - H.R. 3590, "An Act entitled The Patient Protection and Affordable Care Act", regarding all provisions. - H.R. 3962, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.", regarding all provisions. - H.R. 4872, "Health Care and Education Reconciliation Act of 2010", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2009 · fourth_quarter · 4A
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1427, "To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes", regarding all provisions. - H.R. 1548 / S. 726, "To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - S. 1679, "To make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce", regarding all provisions. - S.1796, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions. - H.R. 3200, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions. - H.R. 3590, "An Act entitled The Patient Protection and Affordable Care Act", regarding all provisions. - H.R. 3962, "To provide affordable, quality health care for all Americans and reduce the growth in helaht care spending, and for other purposes.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2009 · fourth_quarter · Q4
- H.R. 2454, "To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy", regarding all provisions. - H.R. 1262, "To amend the Federal Water Pollution Control Act to authorize appropriations for state water pollution control revolving funds, and for other purposes", regarding all provisions. - S. 1005, "A bill to amend the Federal Water Pollution Control Act and the Safe Drinking Water Act to improve water and wastewater infrastructure in the United States", regarding all provisions. - H.R. 1145, "To implement a National Water Research and Development Initiative, and for other purposes", regarding all provisions.
-Corporate tax deferral - H.R. 1897 / S. 803, "To amend the Internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs and for other purposes", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2009 · third_quarter · Q3
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1427, "To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes", regarding all provisions. - H.R. 1548 / S. 726, "To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes", regarding all provisions. - H.R. 2 / S. 275, "To amend title XXI of the Social Security Act to extend and improve the Children's Health Insurance Program, and for other purposes", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - Issues relating to the "Comparative Effectiveness Research Act of 2008", regarding all provisions. - "Affordable Health Choices Act- To make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce", regarding all provisions. - House Energy & Commerce Committee Discussion Draft, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions. - H.R. 3200, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions. - Chairman's Mark, "America's Healthy Future Act of 2009", (bill not yet introduced), regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2009 · second_quarter · Q2
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1427, "To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes", regarding all provisions. - H.R. 1548 / S. 726, "To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes", regarding all provisions. - H.R. 2 / S. 275, "To amend title XXI of the Social Security Act to extend and improve the Children's Health Insurance Program, and for other purposes", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - Issues relating to the "Comparative Effectiveness Research Act of 2008", regarding all provisions. -"Affordable Health Choices Act- To make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce", regarding all provisions. -House Energy & Commerce Committee Discussion Draft, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2009 · first_quarter · Q1
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions.
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1427, "To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes", regarding all provisions. - H.R. 1548 / S. 726, "To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes", regarding all provisions. - H.R. 2 / S. 275, "To amend title XXI of the Social Security Act to extend and improve the Children's Health Insurance Program, and for other purposes", regarding all provisions. - Issues relating to the "Comparative Effectiveness Research Act of 2008", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2008 · fourth_quarter · 4A
-H.R. 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
-H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; -Proposed Rule (CMS-1404-P), "CY 2009 Outpatient Prospective Payment System Rules". -H.R. 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule; -H.R. 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; -H.R. 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; -H.R. 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions; -H.R. 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions; -H.R. 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; -H.R. 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; -H.R. 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007; -H.R. 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children; -S. 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; -S. 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; -S. 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; -CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; -CMS-2238-FC, regarding the Medicaid program, and prescription drugs; -S. 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions. -S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP; -H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; -H.R. 6252, "Medicare DMEPOS Competitive Acquisition Reform Act of 2008", To amend part B of title XVIII of the Social Security Act to delay and reform the Medicare competitive acquisition program for purchase of durable medical equipment, prosthetics, orthotics, and supplies, regarding all provisions; -S. 2404, "Medicare Advanced Laboratory Diagnostics Act of 2007", A bill to amend title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule, regarding all provisions; -H.R. 6331/ S. 3101, "Medicare Improvements for Patients and Providers Act of 2008", A bill to amend titles XVIII and XI of the Social Security Act to extend expiring provisions under the Medicare program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes, regarding all provisions; -H.R. 2770, "To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2008 · fourth_quarter · 4A
-H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations; -H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation; -H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2008 · fourth_quarter · Q4
-H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; -Proposed Rule (CMS-1404-P), "CY 2009 Outpatient Prospective Payment System Rules". -H.R. 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule; -H.R. 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; -H.R. 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; -H.R. 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions; -H.R. 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions; -H.R. 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; -H.R. 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; -H.R. 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007; -H.R. 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children; -S. 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; -S. 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; -S. 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; -CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; -CMS-2238-FC, regarding the Medicaid program, and prescription drugs; -S. 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions. -S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP; -H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; -H.R. 6252, "Medicare DMEPOS Competitive Acquisition Reform Act of 2008", To amend part B of title XVIII of the Social Security Act to delay and reform the Medicare competitive acquisition program for purchase of durable medical equipment, prosthetics, orthotics, and supplies, regarding all provisions; -S. 2404, "Medicare Advanced Laboratory Diagnostics Act of 2007", A bill to amend title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule, regarding all provisions; -H.R. 6331/ S. 3101, "Medicare Improvements for Patients and Providers Act of 2008", A bill to amend titles XVIII and XI of the Social Security Act to extend expiring provisions under the Medicare program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes, regarding all provisions; -H.R. 2770, "To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2008 · third_quarter · Q3
-H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations; -H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation; -H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
-H.R.1165, "Swift Approval, Full Evaluation Drug Act or the 'SAFE Drug Act," regarding amending the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs and to establish whistleblower protections for certain individuals; -H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions;
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2008 · second_quarter · Q2
H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; HR 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule; HR 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; HR 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; HR 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions; HR 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions; HR 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; HR 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; HR 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007; HR 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children; S 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; S 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; S 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; CMS-2238-FC, regarding the Medicaid program, and prescription drugs; S 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions. S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP; H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; H.R. 6252, "To amend part B of title XVIII of the Social Security Act to delay and reform the Medicare competitive acquisition program for purchase of durable medical equipment, prosthetics, orthotics, and supplies", regarding all provisions; S. 2404, "A bill to amend title SVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule", regarding all provisions; H.R. 6331/ S. 3101, "A bill to amend titles XVIII and XIX of the Social Security Act to extend expiring provisions under the Medicare program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes", regarding all provisions.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2008 · first_quarter · Q1
H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; HR 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule; HR 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; HR 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; HR 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions; HR 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions; HR 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; HR 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; HR 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007; HR 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children; S 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; S 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; S 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; CMS-2238-FC, regarding the Medicaid program, and prescription drugs; S 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions. S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP; H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program.
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2007 · year_end · YY
HR 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
HR 3043 / S 1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, regarding appropriations; HR 3161 / S 1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008, regarding drug importation;
HR 1712, Research and Development Tax Credit Act of 2007, regarding amending the Internal Revenue Code of 1986 to provide incentives to improve America's research competitiveness;
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2007 · mid_year · MM
HR 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007,” regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; HR 1494 / S 830, “Pediatric Medical Device Safety and Improvement Act of 2007,” regarding improving the process for the development of needed pediatric medical devices; HR 1956, “Patient Protection and Innovative Biologic Medicines Act of 2007,” regarding amending the Public Health Service Act to provide for the approval of similar biological products; HR 2193, “Animal Protection Accountability Improvement Act,” regarding amending the Animal Welfare Act to increase the penalties for violations of such Act and to prohibit the use of animals for marketing medical devices; HR 2349 / S 1413, “Uterine Fibroid Research and Education Act of 2007,” regarding providing for research and education with respect to uterine fibroids; HR 3333 / S. 1576, “Minority Health Improvement and Health Disparity Elimination Act,” regarding amending the Public Health Service Act to improve the health and healthcare of racial and ethnic minority groups; HR 788 / S 468, “Food and Drug Administration Safety Act of 2007,” regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; HR 2900, “Food and Drug Administration Amendments Act of 2007,” regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; S 1082, “Food and Drug Administration Revitalization Act,” regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; S 1695, “Biologics Price Competition and Innovation Act of 2007,” regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products and to promote innovation in the life sciences; S 467, “Fair Access to Clinical Trials Act of 2007 or the `FACT Act',” regarding amending the Public Health Service Act to expand the clinical trials drug data bank; S 558, “Mental Health Parity Act of 2007,” regarding all provisions; S 628, “Critical Access to Health Information Technology Act of 2007,” regarding providing grants for rural health information technology development activities; S 993, “Pediatric Research Improvement Act,” regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine. HR 1165, “Swift Approval, Full Evaluation Drug Act or the `SAFE Drug Act',” regarding amending the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs and to establish whistleblower protections for certain individuals;
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2006 · year_end · YY
Competitive Bidding for DME Implementation of DRA In-Vitro Diagnostics Legislation Medicare Competitive Acquistion Program (CAP) Medicare Competitive Bidding for Durable Medical Equipment Medicare Fraud and Abuse Medicare Part B Drug Payment Reform Medicare Part D Implementation Medicare Payment Policy Medicare Hospital Outpatient Rule Medicare Pay for Performance - Inpatient Prospective Payment System - Proposed Rule Medicare Coverage of I-BOT Medicaid Reform Mental Health Limitation for Scientific Products Pain Management Legislation Physician Fee Schedule Rule Out Patient Physician System Self-Administration Rule HR 328, HR 376, S 334, S 813 - Medicare Prescription Drug Coverage and Pricing Information HR 4157 - HIT/ICD-10 Coding HR 5179 - Amend Title XVIII of Social Security Act HR 5369 - Advanced Laboratory Diagnostics Act of 2006 HR 5465, S 340 Community Cancer Care Preservation Act of 2006 HR 6063- Remote Monitoring Legislation S 239, S 445 - Medicare Prescription Druge Coverage and Pricing Non-Interference AIDS Drugs Assistance Program Appropriations Chronic Care Improvement Program (CCIP) Clinical Lab Fee Schedule Reimbursement Rates Competitive Bidding for Laboratory Services
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2005 · mid_year · MM
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2004 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2004 · mid_year · MA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2001 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
2000 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Drug Enforcement Administration (DEA), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
JOHNSON & JOHNSON SERVICES INC via JOHNSON & JOHNSON SERVICES, INC.
1999 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
- Issues related to Health Spending Accounts & Flexible Spending Accounts - Issues related to corporate tax provisions of reconciliation bill - U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD") - HR 2096/S 2472 "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions.
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - Issues related to prescription drug pricing - Issues pertaining to Medicare coverage of vaccines - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - HR 446, Expressing support for the goals and ideals of National Stroke Awareness Month - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - S 1784/HR 3353, the Contact Lens Prescription Verification Modernization Act - HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act - Issues related to clinical research diversity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions - Issues related to prescription drug pricing - Issues related to health care pricing transparency - Issues related to maternal health - Issues related to frontline health workers - Issues related to over the counter products - Issues related to the regulation of cosmetic products - Issues related to the regulation of dietary supplements - Issues related to contact lens safety - Issues related to stroke care - Issues related to counterfeit health care goods - Issues related to 340B drug pricing program - Issues related to antimicrobial resistance - Issues related to the COVID-19 vaccine development, including diversity in clinical trials - Issues related to Medicare Part D's 6 protected classes - Issues related to global public health and ending tuberculosis - HR 446, Expressing support for the goals and ideals of National Stroke Awareness Month - S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act" - Issues pertaining to health equity and social determinants of health - Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements - Issues related to lung cancer screening - HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products - Issues related to brand protection - Issues related to e-Commerce - S 936, "INFORM Consumers Act", regarding all provisions - HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Issues related to environmental sustainability - Issues related to recycling and plastics - Issues related to coral reefs
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions - Issues related to ingredient safety - Issues related to animal testing and consumer products - Issues related to counterfeit consumer products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications -H.R.133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B
- Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to CFC look through. - Issues related to the implementation of the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 -"Restoring Access to Medication Act of 2019", regarding all provisions. - H.R. 748/ S. 3458, "Coronavirus Aid, Relief, and. Economic Security Act", regarding tax provisions and future stimulus bills. - Issues related to supply chain investment incentives. - Tax issues related to Puerto Rico
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions - Issues related to sterilization of medical devices - Issues regarding environmental sustainability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to CFC look through. - Issues related to the implementation of the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 -"Restoring Access to Medication Act of 2019", regarding all provisions. - H.R. 748/ S. 3458, "Coronavirus Aid, Relief, and. Economic Security Act", regarding tax provisions and future stimulus bills. - Issues related to supply chain investment incentives.
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions - Issues related to sterilization of medical devices - Issues regarding environmental sustainability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions - Issues related to sterilization of medical devices - Issues regarding environmental sustainability
-Issues related to FY2020 Appropriations, specifically the Special Olympics, The Global Fund, Food & Drug Administration, Commerce, Interior, National Institutes of Health and Environmental Protection Agency budgets. -Issues related to frontline health workers
- Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to replacing G1LT1 global average method with a per country minimum. - Issues related to CFC look through. - Issues related to the implementation of the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 -"Restoring Access to Medication Act of 2019", regarding all provisions. - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding tax provisions and future stimulus bills.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions - H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions - H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions - Issues related to sterilization of medical devices - Issues regarding environmental sustainability
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- Issues related to miscellaneous tax bills. - Issues related to spending and linked to corporate tax rate - H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions - H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions - Issues related to replacing G1LT1 global average method with a per country minimum. - Issues related to CFC look through. - Issues related to the Tax Cut and Jobs Act of 2017 - H.R. 1922/S. 1089 - A bill to amend the Internal Revenue Code of 1986 to repeal the amendments made by the Patient Protection and Affordable Care Act which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements, regarding all provisions. - H.R. 2207/S. 693 "Protect Medical Innovation Act of 2019", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
-Issues related to FY2020 Appropriations, specifically the Special Olympics, The Global Fund, Food & Drug Administration, Commerce, Interior, and Environmental Protection Agency budgets.
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the reputation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to the medical device tax repeal - Issues related to medical product communications - Issues related to medical product review - Issues related to talc safety - Issues related to drug pricing reform - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - H.R. 269 - Pandemic and All-Hazards Preparedness & Advancing Innovation Act of 2019, regarding all provisions - Issues related to the reputation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to the medical device tax repeal - Issues related to medical product communications - Issues related to medical product review - Issues related to talc safety - Issues related to drug pricing reform - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- S.85/H.R.394, "Restoring Access to Medication Act of 2017", regarding all provisions. - Issues related to Mobile Workforce legislation. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Regulations implementing PL 115-97, "Tax Cut & Jobs Act", regarding all provisions.
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions. HR 1892, "BiPartisan Budget Act", regarding all provisions. HR 1625, "Consolidated Appropriations Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions. HR 1892, "BiPartisan Budget Act", regarding all provisions. HR 1625, "Consolidated Appropriations Act", regarding all provisions.
- S.85/H.R.394, "Restoring Access to Medication Act of 2017", regarding all provisions. - Issues related to Mobile Workforce legislation. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Regulations implementing PL 115-97, "Tax Cut & Jobs Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions. HR 1892, "BiPartisan Budget Act", regarding all provisions. HR 1625, "Consolidated Appropriations Act", regarding all provisions.
- S.85/H.R.394, "Restoring Access to Medication Act of 2017", regarding all provisions. - Issues related to tax reform. - Issues related to Mobile Workforce legislation. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Regulations implementing PL 115-97, "Tax Cut & Jobs Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
- S.85/H.R.394, "Restoring Access to Medication Act of 2017", regarding all provisions. - Issues related to tax reform. - Issues related to Mobile Workforce legislation. - Issues related to OECD tax reporting. - Issues related to Puerto Rico tax treatment. - Regulations implementing PL 115-97, "Tax Cut & Jobs Act", regarding all provisions.
S.Con.Res. 3, "A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.", regarding all provisions. HR 1892, "BiPartisan Budget Act", regarding all provisions. HR 1625, "Consolidated Appropriations Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - Issues related to over the counter medicine regulatory reform - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - Issues related to 21st Century Cures Act. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2430, FDA Reauthorization Act - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues related to user fees. - Issues regarding drug pricing. - Issues related to diagnostic reform. - Issues related to blood glucose meters. - Issues related to 21st Century Cures Act. - Issues related to CDC guidelines related to surgical site infections. - Issues related to FDA inspections legislation (not yet introduced)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to CFC Look through permanency. - Issues related to R&D credit. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Repatriation holiday. - Issues related to Puerto Rico tax treatment. - Issues related to flexible spending accounts tax treatment. - HR 4900/ HR 5278/ S 2328, "PROMESA", regarding provisions related to Puerto Rico debt restructuring. - H.Res 770, "Providing for consideration of the bill (H.R. 5278) to establish an Oversight Board to assist the Government of Puerto Rico, including instrumentalities, in managing its public finances, and for other purposes.", regarding all provisions. - Issues related to treasury debt/equity rules.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 2777, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package - Issues related to Self monitoring of blood glucose meters. - HR 4075, "Cosmetic Modernization Amendments of 2015", regarding all provisions. - HR 1192, "National Clinical Care Commission Act", regarding all provisions.
- Issues relating to animal testing. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - Issues related to Medicare Part B Demo - Issues related to Expanded Access in Senate Innovation Package - Issues related to Self monitoring of blood glucose meters. - HR 4075, "Cosmetic Modernization Amendments of 2015", regarding all provisions.
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - Issues related to FDA Funding. - Issues related to VA procurement. - S. 3067/ HR 5485 - Financial Services and General Appropriations Act of 2017 - Issues related to FTC funding.
- S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues relating to animal testing. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to CFC Look through permanency. - Issues related to R&D credit. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Repatriation holiday. - Issues related to Puerto Rico tax treatment. - Issues related to flexible spending accounts tax treatment. - HR 4900/ HR 5278/ S 2328, "PROMESA", regarding provisions related to Puerto Rico debt restructuring. - H.Res 770, "Providing for consideration of the bill (H.R. 5278) to establish an Oversight Board to assist the Government of Puerto Rico, including instrumentalities, in managing its public finances, and for other purposes.", regarding all provisions.
- S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding. - Issues related to VA procurement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to CFC Look through permanency. - Issues related to R&D credit. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Repatriation holiday. - Issues related to Puerto Rico tax treatment. - Issues related to flexible spending accounts tax treatment.
- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to CFC Look through permanency. - Issues related to R&D credit. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Repatriation holiday. - Issues related to Puerto Rico tax treatment.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions. - S. 1622, "The FDA Devise Accountablility Act", regarding all provisions. - S. 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions. - HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding.
- S 620, "Preserving Employee Wellness Programs Act", regarding all provisions.
- Issues relating to animal testing. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to CFC Look through permanency. - Issues related to R&D credit. - Issues related to Mobile Workforce legislation. - Issues related to Cadillac Tax. - Issues related to OECD tax reporting. - Issues related to Repatriation holiday. - Issues related to Puerto Rico tax treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding.
- Issues relating to animal testing.
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions. - Issues related to tax reform. - Issues related to Look through permanency. - Issues related to R&D credit permanency. - Issues related to Mobile Workforce. - Issues related to Cadillac Tax. - Issues related to OECD tax reports. - Issues related to Repatriation holiday.
- HR 1321, "Microbead-Free Waters Act of 2015", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- S 620, "Preserving Employee Wellness Programs Act", regarding all provisions.
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - S 1622, "FDA Device Accountability Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- S 620, "Preserving Employee Wellness Programs Act", regarding all provisions.
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions. - HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - Issues related to 21st Century Cures. - Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues relating to cosmetic regulatory reform. - Issues related to 340B payments to hospitals. - Issues related to pseudoephedrine. - Issues related to dextromethorphan. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to legislation that would establish a rebate in the Medicare Part D program.
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally. - Issues related to the funding of the Biomedical Advanced Research and Development Authority. - FDA Funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- S.1009, "Chemical Safety Improvement Act", regarding all provisions.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - Issues related to health care associated infections. - S 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions. - Issues related to FDA regulation of custom medical devices. - Issues related to Tricare coverage of Total Disc Arthroplasty. - Issues related to VA requirements for vendor access and credentialing. - Issues related to 21st Century Cures. - Issues related to Medicare beneficiary access. - Issues related to mobile medical applications and digital healthcare. - Issues related to FDA draft guidances on blood glucose meters. - HR 4895/ S 2902, "The Microbead Free Waters Act of 2014", regarding all provisions. - Issues related to the expanded use of unapproved drugs. - Issues related to combination products. - Issues related to the PROTECT Act (bill number pending), specifically medical mobile applications. - Issues related to Government Health Care Exclusion/ Debarment (bill number pending) - S 2977, "MEDTECH Act", regarding provisions related to medical mobile applications. - S 2917, "Adding Ebola to the FDA Priority Review Voucher Program Act", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to debt ceiling.- HR 83, Consolidate and Further Continuing Appropriations Act, 2015, provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
- S.1009, "Chemical Safety Improvement Act", regarding all provisions. - Ortho Clinical Diagnostics liability issue related to the EPA.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to debt ceiling.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means and Senate Finance tax reform discussion drafts.- HR 1129 / S 1645, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions. - HR 2992, "Business Activity Tax Simplification Act", regarding all provisions. - HR 2835, "Restoring Access to Medication Act", regarding all provisions. - Issues related to OECD tax project.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644/ HR 3969, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - HR 2085, "Diagnostic Payment Reform", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - HR 4015, "SGR Repeal and Medicare Provider Payment Modernization Act of 2014", regarding all provisions. - Issues related to health care associated infections. - S 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions. - Issues related to FDA regulation of custom medical devices. - Issues related to Tricare coverage of Total Disc Arthroplasty. - Issues related to VA requirements for vendor access and credentialing. - Issues related to 21st Century Cures. - Issues related to Medicare beneficiary access. - Issues related to mobile medical applications and digital healthcare. - Issues related to FDA draft guidances on blood glucose meters. - HR 4895, "The Microbead Free Waters Act of 2014", regarding all provisions. - Issues related to the expanded use of unapproved drugs.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to debt ceiling.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- S.1009, "Chemical Safety Improvement Act", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to debt ceiling.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means and Senate Finance tax reform discussion drafts.- HR 1129 / S 1645, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions. - HR 2992, "Business Activity Tax Simplification Act", regarding all provisions. - HR 2835, "Restoring Access to Medication Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to appropriations/debt ceiling.
- S.1009, "Chemical Safety Improvement Act", regarding all provisions.
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means and Senate Finance tax reform discussion drafts.- HR 1129, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions. - HR 2992, "Business Activity Tax Simplification Act", regarding all provisions. - HR 2835, "Restoring Access to Medication Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - HR 2375, "Competitive Bidding for DME Delay", regarding all provisions. - Issues related to health care pricing transparency. - Issues related to Mobile Medical Application draft legislation. - HR 2085, "Diagnostic Payment Reform", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means tax reform discussion draft.- HR 1129, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions. - HR 2992, "Business Activity Tax Simplification Act", regarding all provisions. - HR 2835, "Restoring Access to Medication Act", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues related to chemicals in the environment. - PL 94-469, "Toxic Substances Control Act", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to deficit reductions/fiscal cliff.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means tax reform discussion draft.- HR 523, "Protect Medical Innovation Act of 2013", regarding all provisions. - HR 1295, "Medical Device Tax Elimination Act", regarding all provisions. - S 232, "Medical Device Access and Innovation Protection Act", regarding all provisions. - HR 1129, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - HR 2375, "Competitive Bidding for DME Delay", regarding all provisions.
- Issues regarding tax reform. - HR 1248, "Family Health Care Flexibility Act", regarding all provisions. - Issues related to tax legislation. - Issues related to Ways and Means tax reform discussion draft.- HR 1295, "Medical Device Tax Elimination Act", regarding all provisions. - S 232, "Medical Device Access and Innovation Protection Act", regarding all provisions. - HR 1129, "Mobile Workforce State Income Tax Simplification Act of 2013", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Alzheimer's research. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - S 622, "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013", regarding all provisions. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - PL 11229, "Leahy-Smith America Invents Act" and issues related to patent trolls. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program.
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
- Issues related to chemicals in the environment. - PL 94-469, "Toxic Substances Control Act", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Products. - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions. - HR 4395, "Cosmetic Safety Amendments Act of 2012", regarding all provisions. - HR 4262, "Cosmetic Safety Enhancement Act of 2012", regarding all provisions. - S 3376, "Prevent Abuse of Cough Treatment Act of 2012", regarding all provisions.
- Issues related to ADAP funding. - Issues related to FDA funding. - Issues related to Alzheimer's funding. - Issues related to deficit reductions/ fiscal cliff
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Prescription Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA. - Medical Device User Fee Act Reauthorization. - HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions. - HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions. - HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions. - S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions. - S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions. - HR 5, "Protecting Access to Healthcare (PATH) Act", regarding all provisions. - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - HR 5937, "Breast Cancer Patient Education Act of 2012", regarding all provisions. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions. - S 3187, "Food and Drug Administration Safety and Innovation Act", regarding all provisions. - S 2516, "Food and Drug Administration Safety and Innovation Act", regarding all provisions. - HR 6584, Verifying Authority and Legality In Drug Compounding Act of 2012, regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues generating antibiotic incentives. - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Prescription Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA. - Medical Device User Fee Act Reauthorization. - HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions. - HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions. - HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions. - S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions. - S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions. - HR 5, "Protecting Access to Healthcare (PATH) Act", regarding all provisions. - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - HR 5937, "Breast Cancer Patient Education Act of 2012", regarding all provisions. - HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions. - S 3187, "Food and Drug Administration Safety and Innovation Act", regarding all provisions. - S 2516, "Food and Drug Administration Safety and Innovation Act", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Products. - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions.
- Issues related to ADAP funding. - Issues related to the Joint Committe on Deficit Reduction. - Issues related to FDA funding. - Issues related to Alzheimer's funding.
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues generating antibiotic incentives. - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Prescription Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3209, "Premarket Predictability Act of 2011", regarding all provisions. - HR 3203/ S 1943, "Novel Device Regulatory Relief Act of 2011", regarding all provisions. - HR 3230, "Keeping America Competitive Through Harmonization Act of 2011", regarding all provisions. - HR 3211, "Humanitarian Device Reform Act of 2011", regarding all provisions. - HR 3208, "Patients Come First Act of 2011", regarding all provisions. - HR 3206, "Cultivating Scientific Expertise to Foster Inovation for Patients Act of 2011", regarding all provisions. - HR 3214/ S 1972, "Food and Drug Administration Mission Reform Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - HR 3204, "Guidance Accountability and Transparency Act of 2011", regarding all provisions. - HR 3205, "FDA Renewing Efficiency From Outside Reviewer Management Act of 2011", regarding all provisons. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA. - Medical Device User Fee Act Reauthorization. - HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions. - HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions. - HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions. - S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions. - S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions. - HR 5, "Protecting Acess to Healthcare (PATH) Act", regarding all provisions. - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards.
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - Issues related to Physician Payment Sunshine provisions. - Issues generating antibiotic incentives. - Issues related to the Better Act - HR 1282, "Generating Antibiotics Incentives Now Act of 2011", regarding all provisions. - Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions. - Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions. - HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions. - Physician Drug User Fee Act, regarding all provisions - Personalized Medicine Incentives and Regulation. - Issues related to Alzheimer's research. - HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions. - HR 3497, "MODERN Cures Act of 2011", regarding all provisions. - HR 3209, "Premarket Predictability Act of 2011", regarding all provisions. - HR 3203/ S 1943, "Novel Device Regulatory Relief Act of 2011", regarding all provisions. - HR 3230, "Keeping America Competitive Through Harmonization Act of 2011", regarding all provisions. - HR 3211, "Humanitarian Device Reform Act of 2011", regarding all provisions. - HR 3208, "Patients Come First Act of 2011", regarding all provisions. - HR 3206, "Cultivating Scientific Expertise to Foster Inovation for Patients Act of 2011", regarding all provisions. - HR 3214/ S 1972, "Food and Drug Administration Mission Reform Act of 2011", regarding all provisions. - HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions. - HR 3204, "Guidance Accountability and Transparency Act of 2011", regarding all provisions. - HR 3205, "FDA Renewing Efficiency From Outside Reviewer Management Act of 2011", regarding all provisons. - S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions. - S 1865, "Patient Access to Medical Innovation Act", regarding all provisions. - S 1995, "Medical Device Patient Safety Act", regarding all provisions. - Issues related to vision care coverage under PPACA.
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Products. - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions.
- Issues related to ADAP funding. - Issues related to the Joint Committe on Deficit Reduction. - Issues related to FDA funding.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues related to chemicals in the environment - Issues related to the Toxic Substances Control Act - S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Products. - Issues relating to the McNeil recall of over the counter medications - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions.
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions
- Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions. - HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions. - Medicare Part D Letter - HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions. - S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions.
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Productions - Isses relating to the McNeil recall of over the counter medications - HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- Issues related to dextromethorphan - Issues related to Pseudoephedrine - Issues related to the regulation of Cosmetic Productions - Isses relating to the McNeil recall of over the counter medications
- Issues related to ensuring quality of supply chain for FDA regulated products - Issues generating antibiotic incentives - Issues regarding personalized medicine.
- Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit. - HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions. - HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
- H.R. 1508 / S. 537,"A bill to amend chapter 111 of title 28, United States Code, relating to protective orders, sealing of cases, disclosures of discovery information in civil actions, and for other purposes", regarding all provisions. - Problems with over criminalization. - S. 1504, "A bill to provide that Federal courts shall not dismiss complaints under rule 12(b)(6) or (e) of the Federal Rules of Civil Procedure, except under the standards set forth by the Supreme Court of the United States in Conley v. Gibson, 355 U.S. 41 (1957)", regarding all provisions. - H.R. 4115, "To amend title 28, United States Code, to provide a restoration of notice pleading in Federal courts, and for other purposes", regarding all provisions.
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications. - H.R. 2923, "A bill to Enhance the ability to combat Methamphetamine", regarding all provisions. - H.R. 5786, "Safe Cosmetics Act of 2010", regarding all provisions.
- H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 3962, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - S. 3397, "An Act to Amend the Controlled Substances Act to provide for take-back Disposal of Controlled Substances in certain instances and for other purposes", regarding all provisions. - H.R. 6331, "Generating Antibiotic Incentives Now Act of 2010", regarding all provisions.
- H.R. 2454, "To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy", regarding all provisions. - H.R. 1262, "To amend the Federal Water Pollution Control Act to authorize appropriations for state water pollution control revolving funds, and for other purposes", regarding all provisions. - S. 1005, "A bill to amend the Federal Water Pollution Control Act and the Safe Drinking Water Act to improve water and wastewater infrastructure in the United States", regarding all provisions. - H.R. 1145, "To implement a National Water Research and Development Initiative, and for other purposes", regarding all provisions. - H.R. 5820, "Toxic Chemicals Safety Act of 2010", regarding all provisions. - S. 3209, "Safe Chemicals Act of 2010", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 2454, "To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy", regarding all provisions. - H.R. 1262, "To amend the Federal Water Pollution Control Act to authorize appropriations for state water pollution control revolving funds, and for other purposes", regarding all provisions. - S. 1005, "A bill to amend the Federal Water Pollution Control Act and the Safe Drinking Water Act to improve water and wastewater infrastructure in the United States", regarding all provisions. - H.R. 1145, "To implement a National Water Research and Development Initiative, and for other purposes", regarding all provisions.
- H.R. 1508 / S. 537,"A bill to amend chapter 111 of title 28, United States Code, relating to protective orders, sealing of cases, disclosures of discovery information in civil actions, and for other purposes", regarding all provisions. - Problems with over criminalization. - S. 1504, "A bill to provide that Federal courts shall not dismiss complaints under rule 12(b)(6) or (e) of the Federal Rules of Civil Procedure, except under the standards set forth by the Supreme Court of the United States in Conley v. Gibson, 355 U.S. 41 (1957)", regarding all provisions. - S. 1578, "A bill to amend chapter 171 of title 28, United States Code, (commonly referred to as the Federal Torts Claim Act) to extend medical malpractice coverage to free clinics and the officers, governing board members, employees, and contractors of free clinics in the same manner and extend as certain Federal officers and employees.", regarding all provisions. - H.R. 4115, "To amend title 28, United States Code, to provide a restoration of notice pleading in Federal courts, and for other purposes", regarding all provisions.
- CMS 4138-IFC4, "Medicare Advantage and Prescription Drug Programs MIPPA Drug Formulary and Protected Classes Policies", regarding all provisions. - H.R. 684 / S. 330, "To amend title XVIII of the Social Security Act to deliver a meaningful benefit and lower prescription drug prices under the Medicare Program", regarding all provisions. - S. 883, "A bill to amend title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV", regarding all provisions. - H. R. 1616, "To amend title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV", regarding all provisions. - H. R. 1392 / S. 1221, "A bill to amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sale price", regarding all provisions. - H.R. 3138/ S. 301, "A bill to amend title XI of the Social Security Act to provide for transparancy in the relationship between physicians and manufacturers of drugs, devices, biologicals, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP. - Implementation of Health Care Reform Bill: Medicare Wellness Benefit. - H.R. 6130, "Strengthening Medicare Anti-Fraud Measures Act of 2010", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 1508 / S. 537,"A bill to amend chapter 111 of title 28, United States Code, relating to protective orders, sealing of cases, disclosures of discovery information in civil actions, and for other purposes", regarding all provisions. - S. 1504, "A bill to provide that Federal courts shall not dismiss complaints under rule 12(b)(6) or (e) of the Federal Rules of Civil Procedure, except under the standards set forth by the Supreme Court of the United States in Conley v. Gibson, 355 U.S. 41 (1957)", regarding all provisions. - S. 1578, "A bill to amend chapter 171 of title 28, United States Code, (commonly referred to as the Federal Torts Claim Act) to extend medical malpractice coverage to free clinics and the officers, governing board members, employees, and contractors of free clinics in the same manner and extend as certain Federal officers and employees.", regarding all provisions. - H.R. 4115, "To amend title 28, United States Code, to provide a restoration of notice pleading in Federal courts, and for other purposes", regarding all provisions.
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346/ S. 540, "Medical Device Safety Act of 2009", regarding all provisions. - Issues relating to the McNeil recall of over the counter medications.
- H.R. 2454, "To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy", regarding all provisions. - H.R. 1262, "To amend the Federal Water Pollution Control Act to authorize appropriations for state water pollution control revolving funds, and for other purposes", regarding all provisions. - S. 1005, "A bill to amend the Federal Water Pollution Control Act and the Safe Drinking Water Act to improve water and wastewater infrastructure in the United States", regarding all provisions. - H.R. 1145, "To implement a National Water Research and Development Initiative, and for other purposes", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 2454, "To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy", regarding all provisions. - H.R. 1262, "To amend the Federal Water Pollution Control Act to authorize appropriations for state water pollution control revolving funds, and for other purposes", regarding all provisions. - S. 1005, "A bill to amend the Federal Water Pollution Control Act and the Safe Drinking Water Act to improve water and wastewater infrastructure in the United States", regarding all provisions. - H.R. 1145, "To implement a National Water Research and Development Initiative, and for other purposes", regarding all provisions.
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions.
- H.R. 1508 / S. 537,"A bill to amend chapter 111 of title 28, United States Code, relating to protective orders, sealing of cases, disclosures of discovery information in civil actions, and for other purposes", regarding all provisions. - S. 1504, "A bill to provide that Federal courts shall not dismiss complaints under rule 12(b)(6) or (e) of the Federal Rules of Civil Procedure, except under the standards set forth by the Supreme Court of the United States in Conley v. Gibson, 355 U.S. 41 (1957)", regarding all provisions. - S. 1578, "A bill to amend chapter 171 of title 28, United States Code, (commonly referred to as the Federal Torts Claim Act) to extend medical malpractice coverage to free clinics and the officers, governing board members, employees, and contractors of free clinics in the same manner and extend as certain Federal officers and employees.", regarding all provisions. - H.R. 4115, "To amend title 28, United States Code, to provide a restoration of notice pleading in Federal courts, and for other purposes", regarding all provisions.
-Corporate tax deferral - H.R. 1897 / S. 803, "To amend the Internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs and for other purposes", regarding all provisions. - H.R. 4213, "American Workers, State, and Business Relief Act of 2010", regarding provisions related to individual and business tax incentives. - S. 3018, "The Bipartisan Tax Fairness and Simplification Act of 2010", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 2454, "To create clean energy jobs, achieve energy independence, reduce global warming pollution and transition to a clean energy economy", regarding all provisions. - H.R. 1262, "To amend the Federal Water Pollution Control Act to authorize appropriations for state water pollution control revolving funds, and for other purposes", regarding all provisions. - S. 1005, "A bill to amend the Federal Water Pollution Control Act and the Safe Drinking Water Act to improve water and wastewater infrastructure in the United States", regarding all provisions. - H.R. 1145, "To implement a National Water Research and Development Initiative, and for other purposes", regarding all provisions.
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions.
- H.R. 1508 / S. 537,"A bill to amend chapter 111 of title 28, United States Code, relating to protective orders, sealing of cases, disclosures of discovery information in civil actions, and for other purposes", regarding all provisions. - S. 1504, "A bill to provide that Federal courts shall not dismiss complaints under rule 12(b)(6) or (e) of the Federal Rules of Civil Procedure, except under the standards set forth by the Supreme Court of the United States in Conley v. Gibson, 355 U.S. 41 (1957)", regarding all provisions. - S. 1578, "A bill to amend chapter 171 of title 28, United States Code, (commonly referred to as the Federal Torts Claim Act) to extend medical malpractice coverage to free clinics and the officers, governing board members, employees, and contractors of free clinics in the same manner and extend as certain Federal officers and employees.", regarding all provisions. - H.R. 4115, "To amend title 28, United States Code, to provide a restoration of notice pleading in Federal courts, and for other purposes", regarding all provisions.
-Corporate tax deferral - H.R. 1897 / S. 803, "To amend the Internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs and for other purposes", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions. - S. 1383, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions.
- H.R. 1897 / S. 803, "A bill to amend the internal Revenue Code of 1986 to provide a tax credit to employers for the costs of implementing wellness programs, and for other purposes", regarding all provisions. - H.R. 759, "To amend the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market, and for other purposes", regarding all provisions. - H.R. 1427, "To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes", regarding all provisions. - H.R. 1548 / S. 726, "To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes", regarding all provisions. - H.R. 1296, "To achieve access to comprehensive primary health care services for all Americans and to reform the organization of primary care delivery through an expansion of the Community Health Center and National Health Service Corps programs", regarding all provisions. - S. 1679, "To make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce", regarding all provisions. - S.1796, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions. - H.R. 3200, "To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes", regarding all provisions. - H.R. 3590, "An Act entitled The Patient Protection and Affordable Care Act", regarding all provisions. - H.R. 3962, "To provide affordable, quality health care for all Americans and reduce the growth in helaht care spending, and for other purposes.
- H.R. 1508 / S. 537,"A bill to amend chapter 111 of title 28, United States Code, relating to protective orders, sealing of cases, disclosures of discovery information in civil actions, and for other purposes", regarding all provisions. - S. 1504, "A bill to provide that Federal courts shall not dismiss complaints under rule 12(b)(6) or (e) of the Federal Rules of Civil Procedure, except under the standards set forth by the Supreme Court of the United States in Conley v. Gibson, 355 U.S. 41 (1957)", regarding all provisions. - S. 1578, "A bill to amend chapter 171 of title 28, United States Code, (commonly referred to as the Federal Torts Claim Act) to extend medical malpractice coverage to free clinics and the officers, governing board members, employees, and contractors of free clinics in the same manner and extend as certain Federal officers and employees.", regarding all provisions. - H.R. 4115, "To amend title 28, United States Code, to provide a restoration of notice pleading in Federal courts, and for other purposes", regarding all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions.
- S. Con. Res. 13, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2010, revising the appropriate budgetary levels for fiscal year 2009, and setting forth the appropriate budgetary levels for fiscal years 2011 through 2014.", regarding all provisions. - H. Con. Res. 85, "Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.", regarding all provisions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
- H.R. 1259, "To amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes", regarding all provisions. - H.R. 1346 / S. 540, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions. - S. 1142, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to inclusion of effectiveness information in drug and device labeling and advertising", regarding all provisions. - H.R. 2502, "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes", regarding all provisions. - S. 882, "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes", regarding all provisions.
- S. Con. Res. 13, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2010, revising the appropriate budgetary levels for fiscal year 2009, and setting forth the appropriate budgetary levels for fiscal years 2011 through 2014.", regarding all provisions. - H. Con. Res. 85, "Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.", regarding all provisions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
-S. 1, "A bill to create jobs, restore economic growth, and strengthen America's middle class through measures that modernize the nation's infrastructure, enhance America's energy independence, expand educational opportunities, preserve and improve affordable health care, provide tax relief, and protect those in greatest need, and for other purposes", regarding all provisions. - H.R. 1, "Making supplemental appropriations for job preservation and creation, infrastructure investment, energy efficiency and science, assistance to the unemployed, and State and local fiscal stabilization, for fiscal year ending September 30, 2009, and for other purposes", regarding all provisions. - S. Con. Res. 13, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2010, revising the appropriate budgetary levels for fiscal year 2009, and setting forth the appropriate budgetary levels for fiscal years 2011 through 2014.", regarding all provisions. - H. Con. Res. 85, "Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.", regarding all provisions.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
-H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations; -H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation; -H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.
-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions. -S.2071, "A bill to enhance the ability to combat methamphetamine", regarding all provisions.
-H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. -S. 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program; -S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -S. 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -H.R. 4083 / S. 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of monographs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes; -S. 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
-H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; -Proposed Rule (CMS-1404-P), "CY 2009 Outpatient Prospective Payment System Rules". -H.R. 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule; -H.R. 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; -H.R. 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; -H.R. 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions; -H.R. 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions; -H.R. 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; -H.R. 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; -H.R. 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007; -H.R. 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children; -S. 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; -S. 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; -S. 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; -CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; -CMS-2238-FC, regarding the Medicaid program, and prescription drugs; -S. 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions. -S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP; -H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; -H.R. 6252, "Medicare DMEPOS Competitive Acquisition Reform Act of 2008", To amend part B of title XVIII of the Social Security Act to delay and reform the Medicare competitive acquisition program for purchase of durable medical equipment, prosthetics, orthotics, and supplies, regarding all provisions; -S. 2404, "Medicare Advanced Laboratory Diagnostics Act of 2007", A bill to amend title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule, regarding all provisions; -H.R. 6331/ S. 3101, "Medicare Improvements for Patients and Providers Act of 2008", A bill to amend titles XVIII and XI of the Social Security Act to extend expiring provisions under the Medicare program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes, regarding all provisions; -H.R. 2770, "To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price", regarding all provisions.
-H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. -S. 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program; -S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -S. 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -H.R. 4083 / S. 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of monographs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes; -S. 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
-H.R. 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions. -S.2071, "A bill to enhance the ability to combat methamphetamine", regarding all provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
-H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations; -H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation; -H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans; -H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices; -H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; -H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; -H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; -H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; -H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; -H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; -S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; -S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; -S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; -S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; -S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; -S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; -H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; -H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; -H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; -S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; -H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; -H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; -H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions; -S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions; -H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions; -S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions; -S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions. -S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions. -S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions. -S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions; -S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions. -Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; -S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.
-H.R. 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
-H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. -S. 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program; -S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -S. 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -H.R. 4083 / S. 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of monographs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes; -S. 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions. -S.2071, "A bill to enhance the ability to combat methamphetamine", regarding all provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; -S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions; -S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; -S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions.
-H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; -Proposed Rule (CMS-1404-P), "CY 2009 Outpatient Prospective Payment System Rules". -H.R. 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule; -H.R. 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; -H.R. 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; -H.R. 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions; -H.R. 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions; -H.R. 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; -H.R. 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; -H.R. 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007; -H.R. 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children; -S. 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; -S. 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; -S. 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; -CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; -CMS-2238-FC, regarding the Medicaid program, and prescription drugs; -S. 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions. -S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP; -H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program; -H.R. 6252, "Medicare DMEPOS Competitive Acquisition Reform Act of 2008", To amend part B of title XVIII of the Social Security Act to delay and reform the Medicare competitive acquisition program for purchase of durable medical equipment, prosthetics, orthotics, and supplies, regarding all provisions; -S. 2404, "Medicare Advanced Laboratory Diagnostics Act of 2007", A bill to amend title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule, regarding all provisions; -H.R. 6331/ S. 3101, "Medicare Improvements for Patients and Providers Act of 2008", A bill to amend titles XVIII and XI of the Social Security Act to extend expiring provisions under the Medicare program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes, regarding all provisions; -H.R. 2770, "To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price", regarding all provisions.
-H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. -S. 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program; -S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -S. 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; -H.R. 4083 / S. 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of monographs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes; -S. 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
-H.R. 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations; H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation; H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. S 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program; S 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; S 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; HR 4083 / S 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of mongraphs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes; S 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
H.R.1165, "Swift Approval, Full Evaluation Drug Act or the 'SAFE Drug Act," regarding amending the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs and to establish whistleblower protections for certain individuals; H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision o mental health and substance-related disorder benefits under group health plans; H.R. 1494 / S. 830, "Pediactric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediactric medical devices; H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products; H.R. 5839, "To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs", regarding all provisions; S. 334, "A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away", regarding all provisions; H.R. 6381, "To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices", regarding all provisions; S. 438, "A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs", regarding all provisions.
H.R. 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries; S. 2274, "A bill to amed the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes", regarding all provisions; S. 1378, "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes; S. 1276, "A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes", regarding all provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.1165, "Swift Approval, Full Evaluation Drug Act or the 'SAFE Drug Act," regarding amending the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs and to establish whistleblower protections for certain individuals; H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision o mental health and substance-related disorder benefits under group health plans; H.R. 1494 / S. 830, "Pediactric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediactric medical devices; H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products; H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices; H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids; H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups; H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety; H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs; S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products; S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences; S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank; S. 558, "Mental Health Parity Act of 2007," regarding all provisions ; S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities; S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine; H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety; H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production; H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP; S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices; H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services; H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products.
H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations; H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation; H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act; S 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program; S 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; S 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; HR 4083 / S 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of mongraphs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes; S 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HR 1190, Community Cancer Care Preservation Act of 2007, regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries;
S 1145, "Patent Reform Act of 2007;" HR 1908, Patent Reform Act of 2007, regarding amending title 35, United States Code, to provide for patent reform; Thailand Compulsory License.
Issues regarding bilateral free trade agreements with South Korea, Peru, Columbia and Panama.
HR 2762 / S 1494, To amend the Public Health Service Act to reauthorize the special diabetes programs for Type I diabetes and Indians under that Act, regarding all provisions.
HR 1165, Swift Approval, Full Evaluation Drug Act or the 'SAFE Drug Act', regarding amending the Federal Food, Drug, and Cosmetic Act to establish additional authorities to ensure the safe and effective use of drugs and to establish whistleblower protections for certain individuals;
HR 2589, Improving Pharmaceuticals for Children Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act;
S 635, Methamphetamine Remediation Research Act of 2007, regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries.
HR 1591, U.S. Troop Readiness, Veterans' Health, and Iraq Accountability Appropriations Act, 2007, regarding Medicaid rebates; HR 1585, "National Defense Authorization Act for Fiscal Year 2008," regarding TRICARE.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S 41, “Research Competitiveness Act of 2007,” regarding amending the Internal Revenue Code of 1986 to provide incentives to improve America's research competitiveness. HR 1712, “Research and Development Tax Credit Act of 2007,” regarding amending the Internal Revenue Code of 1986 to provide incentives to improve America's research competitiveness; HR 763, “To amend the Internal Revenue Code of 1986 to make permanent the deduction allowable with respect to income attributable to domestic production activities in Puerto Rico,” all provisions;
Issues regarding bilateral free trade agreements with South Korea, Peru, Columbia and Panama.
H Con Res 99, "Revising the congressional budget for the United States Government for fiscal year 2007, establishing the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 through 2012," regarding healthcare funding issues. HR 3043 / S 1710, “Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008,” regarding appropriations; HR 3161 / S 1859, “Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008,” regarding drug importation;
S 242, “Pharmaceutical Market Access and Drug Safety Act of 2007,” regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs; S 251, “Pharmaceutical Market Access Act of 2007,” regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs. HR 2589, “Improving Pharmaceuticals for Children Act of 2007,” regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act; S 1156, “Best Pharmaceuticals for Children Amendments of 2007,” regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program;
S 635, “Methamphetamine Remediation Research Act of 2007,” regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries.
HR 2762 / S 1494, “To amend the Public Health Service Act to reauthorize the special diabetes programs for Type I diabetes and Indians under that Act,” all provisions; S 976, "Genomics and Personalized Medicine Act of 2007," all provisions; S 736, "Laboratory Test Improvement Act," all provisions.
HR 1663, “Medicare Mental Health Modernization Act of 2007,” regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program; HR 1845 / S 1428, “Medicare Durable Medical Equipment Access Act of 2007,” regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program; HR 2770, “To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price,” all provisions; HR 3011, “To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program,” regarding all provisions; HR 3061, “Medicare Part D Drug Class Protection Act of 2007,” regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations; HR 4 / S 3, “Medicare Prescription Drug Price Negotiation Act of 2007,” regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries; HR 976 / S 1893, “Children's Health Insurance Program Reauthorization Act of 2007,” regarding amending the Internal Revenue Code of 1986 to provide tax relief for small businesses; HR 3162, “Children's Health and Medicare Protection Act of 2007,” regarding improving enrollment and retention of eligible children; S 1887, “Medicare Access to Critical Medications Act of 2007,” regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program; S 631, “Remote Monitoring Access Act of 2007,” regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program; S 860, “Early Treatment for HIV Act of 2007,” regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV; CMS-1270-F, “Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues,” regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions; CMS-2238-FC, regarding the Medicaid program, and prescription drugs. HR 1190, “Community Cancer Care Preservation Act of 2007,” regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries; HR 1321, “Medicare Advanced Laboratory Diagnostics Act of 2007,” regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule;
HR 1591, “U.S. Troop Readiness, Veterans' Health, and Iraq Accountability Appropriations Act, 2007,” regarding medicaid rebates.
HR 1908, “Patent Reform Act of 2007,” regarding amending title 35, United States Code, to provide for patent reform; Thailand Compulsory License.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Authorized Generics Patent Reform Follow-On Biologics Hatch-Waxman Reform
HR 5384 - FY 2007 Agriculture Appropriations HCR 376, SCR 83 - FY 2007 Budget Resolution HR 5647, S 3708 - FY 2007 Labor, Health, Human Services Appropriations HR 5385, S 3708 - FY 2007 Military Quality of Life Appropriations
HR 1736, S 627 - R&D Tax Credit HR 2830 - Pension Protection Act of 2005
P.L. 109-2 - Class Action Reform HR 1038 - Multi-district Litigation Restoration Act of 2005 HR 4838 - Medical Malpractice Reform Act of 2006
Ryan White Reauthorization Act HR 575 - Say No to Drug Ads Act HR 810 - Stem Cell HR 870 - PhRMA Act of 2005 HR 1457 - Health Information Technology Act of 2005 HR 2090 - Food and Drug Administration Improvement Act of 2005 HR 3196, S 470 - Fair Access to Clinical Trails Act HR 3204 - Public Health Service Act HR 3696 - Medical Advertising Reform Act HR 4157, S 1418 - Health Information Technology S 1955 - Small Business Health Plans S 3546 - Dietary Supplement and Non-Prescription Drug Consumer Protection Act S 3807 - Enhancing Drug Safety and Innovation Act of 2006 S 3897 - Medicare Access & Data S 4098 - Pediatric Medical Device Safety and Improvement Act of 2006 FDA Regulation of Single-Use Device Re-Processing Hospital Group Purchasing Organizations Pediatric Medical Devices Pharmaceutical Reimportation
US-Korea FTA US-China Enforcement Legislation
HR 314, HR 1446, S 103 - Methamphetamine Abuse HR 3199, US Patriot Act Improvement and Reauthorization (Combat Methamphetamine Included)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office